Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA study of long-term outcomes after conbercept injection in insured patients with wet age-related macular degeneration
ChiCTR1800017606Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of conbercept in exudative macular degeneration, sponsored by West China Hospital of Sichuan University. Primary endpoint: Best corrected visual acuity. Started Feb 2017; status: recruiting.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR1800017606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017606.